Background and purpose
Early predictors of prognosis in patients with acute ischemic stroke may help therapeutic decisions. Several studies have been made on several biochemical markers of ischemic stroke, however 8-hydroxy-2-deoxyguanosine (8OHdG), a novel marker of oxidative DNA stress, has never been studied in human yet. We investigated whether measurements of urinary 8OHdG can predict the course of acute ischemic stroke of middle cerebral artery (MCA) territory. At the same time we measured serum S100β, the astroglial protein which is reported to be correlated to cerebral infarct volume and prognosis, and compared with 8OHdG.
Methods
23 patients were divided into an edaravone-treated group (n=16) and an edaravone non-treated group (n=7). We evaluated efficacy of edaravone by calculating urinary 8-OHdG and plasma S100β per unit volume of cerebral infarction. Urine was collected for 24 h for 8-OHdG measurement and plasma was sampled for S100β analysis at the 3rd, 4th, 5th, 7th, and 14th day after onset. All patients were treated similarly except for edaravone use.
Result
Total urinary 8-OHdG content during the 3rd to 5th day was significantly higher in stroke patients than in non-stroke patients (p<0. 01, Figure 1). The total urinary 8-OHdG contents showed significant correlation to volume of infarction (p<0.05), modified Rankin Scale (p<0.05), and plasma S100β values (p<0.05). Edaravone treatment did not show significant effects on delta 8-OHdG values divided by volume of infarction. In contrast, S100β index (individual S100β values minus value at 14th day divided by volume of infarction) showed significant reduction in the edaravone-treated group (p<0.05).
